New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:17 EDTINCYIncyte to present data from multiple cancer programs at ASCO meeting
Incyte will present new data from its lead cancer programs focused on onco-inflammation, immuno-oncology and myeloproliferative neoplasms at the 50th Annual Meeting of the American Society of Clinical Oncology from May 30 to June 3. Data to be presented include full results from RECAP, the Phase II trial of ruxolitinib in combination with capecitabine in metastatic pancreatic cancer. Topline results showed an overall survival benefit in a pre-specified subgroup analysis of patients. Also being presented are preliminary findings from a Phase I/II study of Incyte’s IDO1 inhibitor, INCB24360, in combination with ipilimumab in patients with metastatic melanoma, designed to examine potential synergy with other cancer immunotherapies. Full results will be presented from the pivotal Phase III RESPONSE trial of ruxolitinib in patients with uncontrolled polycythemia vera, the first Phase III study to evaluate a JAK inhibitor as a treatment for patients with PV, which met its primary endpoint.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
13:01 EDTINCYNomura sees more M&A following AbbVie's acquisition of Pharmacyclics
Nomura believes AbbVie's (ABBV) acquisition of Pharmacyclics (PCYC) supports its call that Receptos (RCPT) and Infinity Pharmaceuticals (ICPT) are on the top of M&A lists given both companies have potential $5B in peaks sales potential and unencumbered assets. Additionally, the firm believes the deal has positive implications for Neutral rated Incyte (INFI) given the potential AbbVie can now evaluate ABT-199 in combination with Incyte's duvelisib and Pharmacyclic's Imbruviea across a range of hematological malignancies.
March 2, 2015
07:31 EDTINCYIncyte appoints Steven Stein as Chief Medical Officer
Subscribe for More Information
February 26, 2015
07:37 EDTINCYIncyte to sponsor U.S. polycythemia vera study
Incyte announced that it is sponsoring the first major observational study of patients living with polycythemia vera in the U.S. PV is a rare and progressive blood cancer that can lead to debilitating symptoms, serious cardiovascular complications, and death.The REVEAL study will seek to describe the real-world clinical burden of PV and how healthcare services are utilized in the management of this disease. Incyte is partnering with approximately 200 community and academic medical centers to conduct the study in the U.S. REVEAL, which recently began enrolling patients, is expected to include 2,000 patients under the supervision of a physician for the active management of PV for a period of three years.
February 23, 2015
07:30 EDTINCYIncyte price target raised to $89 from $75 at Oppenheimer
Oppenheimer increased its price target on Incyte after the company reported that sales of its flagship Jakafi drug had jumped 46% year-over-year in Q4. The firm continues to be upbeat on Jakafi's revenue outlook and the company's pipeline. It keeps an Outperform rating on the shares.
07:06 EDTINCYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use